A live attenuated strain of Yersinia pestis KIM as a vaccine against plague

被引:36
|
作者
Sun, Wei [1 ]
Six, David [2 ]
Kuang, Xiaoying [1 ]
Roland, Kenneth L. [1 ]
Raetz, Christian R. H. [2 ]
Curtiss, Roy, III [1 ]
机构
[1] Arizona State Univ, Ctr Infect Dis & Vaccinol, Biodesign Inst, Tempe, AZ 85287 USA
[2] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA
基金
美国国家卫生研究院;
关键词
Yersinia pestis; Lipid A; Regulated delayed attenuation; Plague vaccine; RECOMBINANT V-ANTIGEN; ESCHERICHIA-COLI; PNEUMONIC PLAGUE; PROTECTS MICE; MOUSE MODEL; VIRULENCE; IMMUNIZATION; IMMUNITY; GENES; IDENTIFICATION;
D O I
10.1016/j.vaccine.2011.01.099
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Yersinia pestis, the causative agent of plague, is a potential weapon of bioterrorism. Y. pestis evades the innate immune system by synthesizing tetra-acylated lipid A with poor Toll-like receptor 4 (TLR4)-stimulating activity at 37 degrees C, whereas hexa-acylated lipid A, a potent TLR4 agonist, is made at lower temperatures. Synthesis of Escherichia coli LpxL, which transfers the secondary laurate chain to the 2'-position of lipid A, in Y. pestis results in production of hexa-acylated lipid A at 37 degrees C, leading to significant attenuation of virulence. Previously, we described a Y. pestis vaccine strain in which crp expression is under the control of the arabinose-regulated araC P-BAD promoter, resulting in a 4-5 log reduction in virulence. To reduce the virulence of the crp promoter mutant further, we introduced E. coli lpxL into the Y. pestis chromosome. The chi 10030( pCD1Ap) (Delta lpxP32::P-lpxL lpxL Delta P-crp21::TT araC P-BAD crp) construct likewise produced hexa-acylated lipid A at 37 degrees C and was significantly more attenuated than strains harboring each individual mutation. The LD50 of the mutant in mice, when administered subcutaneously or intranasally was > 10(7)-times and > 10(4)-times greater than wild type, respectively. Mice immunized subcutaneously with a single dose of the mutant were completely protected against a subcutaneous challenge of 3.6 x 10(7) wild-type Y. pestis and significantly protected (80% survival) against a pulmonary challenge of 1.2 x 10(4) live cells. Intranasal immunization also provided significant protection against challenges by both routes. This mutant is an immunogenic, highly attenuated live Y. pestis construct that merits further development as a vaccine candidate. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2986 / 2998
页数:13
相关论文
共 50 条
  • [21] Rational Considerations about Development of Live Attenuated Yersinia pestis Vaccines
    Sun, Wei
    Curtiss, Roy, III
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2013, 14 (10) : 878 - 886
  • [22] Yersinia pestis Pla Protein Thwarts T Cell Defense against Plague
    Smiley, Stephen T.
    Szaba, Frank M.
    Kummer, Lawrence W.
    Duso, Debra K.
    Lin, Jr-Shiuan
    INFECTION AND IMMUNITY, 2019, 87 (05)
  • [23] Glutathionylation of Yersinia pestis LcrV and Its Effects on Plague Pathogenesis
    Mitchell, Anthony
    Tam, Christina
    Elli, Derek
    Charlton, Thomas
    Osei-Owusu, Patrick
    Fazlollahi, Farbod
    Faull, Kym F.
    Schneewind, Olaf
    MBIO, 2017, 8 (03):
  • [24] Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge
    Branger, Christine G.
    Sun, Wei
    Torres-Escobar, Ascencion
    Perry, Robert
    Roland, Kenneth L.
    Fetherston, Jacqueline
    Curtiss, Roy, III
    VACCINE, 2010, 29 (02) : 274 - 282
  • [25] Yersinia Outer Membrane Vesicles as Potential Vaccine Candidates in Protecting against Plague
    Byvalov, Andrey A.
    Konyshev, Ilya V.
    Uversky, Vladimir N.
    Dentovskaya, Svetlana V.
    Anisimov, Andrey P.
    BIOMOLECULES, 2020, 10 (12) : 1 - 23
  • [26] Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica
    Branger, Christine G.
    Torres-Escobar, Ascencion
    Sun, Wei
    Perry, Robert
    Fetherston, Jacqueline
    Roland, Kenneth L.
    Curtiss, Roy, III
    VACCINE, 2009, 27 (39) : 5363 - 5370
  • [27] Remodeling Yersinia pseudotuberculosis to generate a highly immunogenic outer membrane vesicle vaccine against pneumonic plague
    Wang, Xiuran
    Li, Peng
    Singh, Amit K.
    Zhang, Xiangmin
    Guan, Ziqiang
    Curtiss, Roy
    Sun, Wei
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (11)
  • [28] Oral vaccination against plague using Yersinia pseudotuberculosis
    Demeure, Christian E.
    Derbise, Anne
    Carniel, Elisabeth
    CHEMICO-BIOLOGICAL INTERACTIONS, 2017, 267 : 89 - 95
  • [29] The Yersinia pestis GTPase BipA Promotes Pathogenesis of Primary Pneumonic Plague
    Crane, Samantha D.
    Banerjee, Srijon K.
    Eichelberger, Kara R.
    Kurten, Richard C.
    Goldman, William E.
    Pechous, Roger D.
    INFECTION AND IMMUNITY, 2021, 89 (02)
  • [30] A COMPARISON OF PLAGUE VACCINE, USP AND EV76 VACCINE-INDUCED PROTECTION AGAINST YERSINIA-PESTIS IN A MURINE MODEL
    RUSSELL, P
    ELEY, SM
    HIBBS, SE
    MANCHEE, RJ
    STAGG, AJ
    TITBALL, RW
    VACCINE, 1995, 13 (16) : 1551 - 1556